Urology
Volume 75, Issue 4 , Pages 793-798 , April 2010

Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells

  • Serdar Goktas

      Affiliations

    • Department of Urology, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Yusuf Baran

      Affiliations

    • Hematology Research Center, Gulhane Military Medical School, Ankara, Turkey
    • Department of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey
    • ,
  • Ali U. Ural

      Affiliations

    • Hematology Research Center, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Sertac Yazici

      Affiliations

    • Department of Urology, Gulhane Military Medical School, Ankara, Turkey
    • Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey
    • Corresponding Author InformationReprint requests: Sertac Yazici, M.D., Department of Urology, Gulhane Military Medical School, Etlik, Ankara, Turkey
    • ,
  • Emin Aydur

      Affiliations

    • Department of Urology, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Seref Basal

      Affiliations

    • Department of Urology, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Ferit Avcu

      Affiliations

    • Hematology Research Center, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Aysel Pekel

      Affiliations

    • Department of Immunology, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Bahar Dirican

      Affiliations

    • Department of Radiation Oncology, Gulhane Military Medical School, Ankara, Turkey
    • ,
  • Murat Beyzadeoglu

      Affiliations

    • Department of Radiation Oncology, Gulhane Military Medical School, Ankara, Turkey

Received 28 March 2009

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomical prostatectomy. CA Cancer J Clin. 1999;49:282–296
  3. Zelefsky MJ, Marion C, Fuks Z, et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beamradiotherapy. J Urol. 2003;170:1828–1832
  4. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc. 1999;281:1591–1597
  5. Goktas S, Crawford D. Optimal hormone therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26:162–173
  6. Michels J, Montemurro T, Murray N, et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?. Cancer. 2006;106:1041–1046
  7. Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control. 2006;13:194–198
  8. Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor–related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005;65:4902–4908
  9. An J, Sun Y, Adams J, et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis inducing ligand in prostate cancer. Clin Cancer Res. 2003;9:4537–4545
  10. Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000;6:3719–3728
  11. Ikezoe T, Yang Y, Saito T, et al. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci. 2004;95:271–275
  12. Cao W, Shiverick KT, Namiki K, et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol. 2008;26:509–516
  13. Dreicer R, Petrylak D, Agus D, et al. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007;13:1208–1215
  14. Baran Y, Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol. 2006;28:163–165
  15. Ogretmen B, Schady D, Usta J, et al. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem. 2001;276:24901–24910
  16. Baran Y, Salas A, Senkal CE, et al. Alterations of human longevity assurance gene 1 (LASS1)/sphingosine kinase-1-dependent ceramide generation and metabolism involve in the regulation of imatinib-induced apoptosis and resistance in k562 human chronic myeloid leukemia (cml) cells. J Biol Chem. 2007;282:10922–10934
  17. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18:109–121
  18. Herrmann JL, Briones F, Brisbay S, et al. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 1998;17:2889–2899
  19. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol. 1995;2:503–508
  20. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment of prostate cancer. Cancer Res. 2004;64:5036–5043
  21. Feinman R, Aris VM, Vergano S. Transcriptional gene expression profiles in drug-sensitive and Bcl-2-resistant myeloma cells in response to dexamethasone, arsenic trioxide, and PS-341. Blood. 2001;98:368a
  22. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–16647
  23. Huang S, Pettaway CA, Uehara H, et al. Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20:4188–4197
  24. Zong WX, Edelstein LC, Chen C, et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNF-α-induced apoptosis. Genes Dev. 1999;13:382–387
  25. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29(suppl 1):3–9
  26. Williams S, Pettaway C, Song R, et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003;2:835–843
  27. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys. 2001;50:183–193
  28. Pervan M, Pajonk F, Sun JR, et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol. 2001;24:481–485
  29. Rosser CJ, Reyes AO, Vakar-Lopez F, et al. Bcl-2 is signiffcantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1–6
  30. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108–2121
  31. Hainsworth JD, Meluch AA, Spigel DR, et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer. 2007;5:278–283

PII: S0090-4295(09)00946-7

doi: 10.1016/j.urology.2009.07.1215

Urology
Volume 75, Issue 4 , Pages 793-798 , April 2010

Article Tools

* Image Usage & Resolution